| Literature DB >> 30428389 |
Jalid Sehouli1, Elena Ioana Braicu2, Rolf Richter2, Carsten Denkert3, Paul Jank3, Philipp Sebastian Jurmeister3, Catarina Alisa Kunze3, Jan Budczies3, Sylvia Darb-Esfahani4, Wolfgang Daniel Schmitt3, Alexander Traut5, Jacek Grabowski6, Eliane Tabea Taube3, Helmut Plett7.
Abstract
Low-grade serous ovarian carcinoma (LGSOC) has recently come up as a distinct rare entity of epithelial ovarian cancer. Predictive and prognostic markers are not well studied yet. Because Ki-67 and hormone receptors (HR) have been established as relevant cancer biomarkers in several malignant tumors, we evaluated Ki-67 and HR expression rates by immunohistochemistry in 68 patients with LGSOC. We used a standardized cutoff finder algorithm to analyze prognostic significance for overall survival (OS) and progression-free survival (PFS). Cox regression showed a significant continuous decrease in OS for higher proliferation rates with an HR of 1.07% (95% confidence interval, 1.01%-3.67%; P = .048) but not in PFS (P = .86). Cutoff finder analysis revealed the best possible cutoff for OS at 6.28% (P = .04) and for PFS at 1.85% proliferative activity (P = .04). Estrogen receptors (ERs) were expressed in most LGSOC patients (n = 61; 89.7%), progesterone receptor (PR) in about half of patients (n = 33; 48.5%). For both ER/PR, a statistically significant cutoff for PFS could be determined, which was at 75% of positive tumor cells for ER (P = .02) and at 15% of positive tumor cells for PR (P = .03). For OS, HR expression showed a tendency toward better OS for HR-positive tumors but did not turn out statistically significant. Our results show that Ki-67 is a valuable prognostic marker in the subgroup of LGSOC. We could also show that most LGSOCs express HRs but that this expression is associated with a better PFS, a finding valuable in times of antihormonal therapy in LGSOC.Entities:
Keywords: Hormone receptor; Ki-67; Low-grade serous ovarian carcinoma; Prognostic marker; Proliferative activity
Mesh:
Substances:
Year: 2018 PMID: 30428389 DOI: 10.1016/j.humpath.2018.10.020
Source DB: PubMed Journal: Hum Pathol ISSN: 0046-8177 Impact factor: 3.466